{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:28:27Z","timestamp":1791379707153,"version":"4.3.3"},"reference-count":45,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>In this case report, we present a patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder. Over a 10-year period, our case transitioned from adolescence to adulthood and received antidepressant monotherapy, adjunctive therapy with antipsychotics, lithium, or lamotrigine, several series of electroconvulsive therapy (ECT), ketamine infusion (KET-IFU), compounded ketamine intranasal spray (COM-KET), and intranasal esketamine (ESK). She had seventeen documented hospitalizations, five self-reported hospitalizations, three intensive outpatient program treatments, two partial hospitalization program treatments, and three residential treatments. She attempted suicide seven times. She received five acute ECT series, one series of KET-IFU, one series of acute ESK with weekly ECT, a series of COM-KET treatment for more than two years, and a series of ESK for more than two years. The patient had some short-term benefit from ECT and KET-IFU. However, she had two-years stability with COM-KET or ESK at two different times. She has been relatively stable without hospitalization or suicide attempt with ESK for more than two years, suggesting that patients with TRD with complex representations may benefit from ketamine treatment at different times of life development.<\/jats:p>","DOI":"10.64719\/pb.4534","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"44-55","source":"Crossref","is-referenced-by-count":3,"title":["Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood"],"prefix":"10.64719","volume":"55","author":[{"given":"Keming","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buket","family":"Koparal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evrim Bayrak","family":"Oruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margret A.","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","unstructured":"Thase ME, Rush AJ. When at first you don\u2019t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;(58 Suppl 13):23\u20139."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Fava M. Diagnosis and definition of treatment-resistant depression. Biological Psychiatry. 2003;53(8):649\u2013659.","DOI":"10.1016\/S0006-3223(03)00231-2"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Sackeim HA, Aaronson ST, Bunker MT et al. The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF) Journal of Psychiatric Research. 2019;113:125\u2013136.","DOI":"10.1016\/j.jpsychires.2019.03.021"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Gao K, Wang Z, Chen J et al. Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity. Journal of Affective Disorders. 2013;148(2\u20133):256\u2013264.","DOI":"10.1016\/j.jad.2012.12.004"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Archives of General Psychiatry. 2005;62(10):1097\u20131106.","DOI":"10.1001\/archpsyc.62.10.1097"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2005;62(6):617\u2013627.","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Thaipisuttikul P, Ittasakul P, Waleeprakhon P, Wisajun P, Jullagate S. Psychiatric comorbidities in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:2097\u2013103. doi: 10.2147\/ndt.S72026.","DOI":"10.2147\/ndt.S72026"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gao K. Role of Electroconvulsive Therapy, Ketamine Infusion, and Deep Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Bipolar Depression: A Case Report. Medicina. 2024;60(6):936.","DOI":"10.3390\/medicina60060936"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Leichsenring F, Fonagy P, Heim N et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024;23(1):4\u201325.","DOI":"10.1002\/wps.21156"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen MS, M\u00f8ller L, Bo S et al. The course of borderline personality disorder from adolescence to early adulthood: A 5-year follow-up study. Compr Psychiatry. 2024;132:152478. doi: 10.1016\/j.comppsych.2024.152478.","DOI":"10.1016\/j.comppsych.2024.152478"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rosson S, De Filippis R, Croatto G et al. Brain stimulation and other biological non-pharmacological interventions in mental disorders: an umbrella review. Neuroscience & Biobehavioral Reviews. 2022;139:104743.","DOI":"10.1016\/j.neubiorev.2022.104743"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kellner CH, Knapp R, Husain MM et al. Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial. The British Journal of Psychiatry. 2010;196(3):226\u2013234.","DOI":"10.1192\/bjp.bp.109.066183"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Feske U, Mulsant BH, Pilkonis PA et al. Clinical outcome of ECT in patients with major depression and comorbid borderline personality disorder. American Journal of Psychiatry. 2004;161(11):2073\u20132080.","DOI":"10.1176\/appi.ajp.161.11.2073"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Steinholtz L, Reutfors J, Brandt L et al. Response rate and subjective memory after electroconvulsive therapy in depressive disorders with psychiatric comorbidity. J Affect Disord. 2021;292:276\u2013283. doi: 10.1016\/j.jad.2021.05.078.","DOI":"10.1016\/j.jad.2021.05.078"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Liu Y, Yang J, Liu Y. Ketamine and electroconvulsive therapy for severe depression: A network meta-analysis of efficacy and safety. Journal of Psychiatric Research. 2024;175:218\u2013226.","DOI":"10.1016\/j.jpsychires.2024.05.022"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Anderson IM, Blamire A, Branton T et al. Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. The Lancet Psychiatry. 2017;4(5):365\u2013377.","DOI":"10.1016\/S2215-0366(17)30077-9"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Nagi T, Jagtiani A, Somvanshi S et al. Ketamine Augmentation of Electroconvulsive Therapy: A Scoping Review of Dose-Dependent Effects in Major Depressive Disorder. Cureus. 2023;15(6):e40087. doi: 10.7759\/cureus.40087.","DOI":"10.7759\/cureus.40087"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Nikolin S, Rodgers A, Schwaab A et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine. 2023;62:102127.","DOI":"10.1016\/j.eclinm.2023.102127"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Roth\u00e4rmel M, Benosman C, El-Hage W et al. Efficacy and safety of intranasal esketamine in patients with treatment-resistant depression and comorbid chronic post-traumatic stress disorder: open-label single-arm pilot study. Frontiers in psychiatry. 2022;13:865466.","DOI":"10.3389\/fpsyt.2022.865466"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Martinotti G, Chiappini S, Pettorruso M et al. Therapeutic potentials of ketamine and esketamine in obsessive\u2013compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature. Brain Sciences. 2021;11(7):856.","DOI":"10.3390\/brainsci11070856"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Keeler JL, Treasure J, Juruena MF, Kan C, Himmerich H. Ketamine as a treatment for anorexia nervosa: a narrative review. Nutrients. 2021;13(11):4158.","DOI":"10.3390\/nu13114158"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Ragnhildstveit A, Slayton M, Jackson LK et al. Ketamine as a novel psychopharmacotherapy for eating disorders: Evidence and future directions. Brain Sciences. 2022;12(3):382.","DOI":"10.3390\/brainsci12030382"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Fineberg SK, Choi EY, Shapiro-Thompson R et al. A pilot randomized controlled trial of ketamine in Borderline Personality Disorder. Neuropsychopharmacology. 2023;48(7):991\u2013999.","DOI":"10.1038\/s41386-023-01540-4"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Danayan K, Chisamore N, Rodrigues NB et al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Research. 2023;323:115133.","DOI":"10.1016\/j.psychres.2023.115133"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Anand A, Mathew SJ, Sanacora G et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine. 2023;388(25):2315\u20132325.","DOI":"10.1056\/NEJMoa2302399"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ekstrand J, Fattah C, Persson M et al. Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT) International Journal of Neuropsychopharmacology. 2022;25(5):339\u2013349.","DOI":"10.1093\/ijnp\/pyab088"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Phillips JL, Norris S, Talbot J et al. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Am J Psychiatry. 2019;176(5):401\u2013409. doi: 10.1176\/appi.ajp.2018.18070834.","DOI":"10.1176\/appi.ajp.2018.18070834"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Swainson J, Klassen LJ, Brennan S et al. Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. CNS Drugs. 2022;36(3):239\u2013251. doi: 10.1007\/s40263-022-00897-2.","DOI":"10.1007\/s40263-022-00897-2"},{"key":"ref29","unstructured":"[Accessed 20\/02\/2025]; FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray. https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Berman J, Ambrose AJ. Prioritizing patient preferences: a practical guide for tailoring treatment choices in interventional psychiatry. The Journal of Clinical Psychiatry. 2022;83(3):40794.","DOI":"10.4088\/JCP.22ac14436"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen MS, M\u00f8ller L, Bo S et al. The course of borderline personality disorder from adolescence to early adulthood: A 5-year follow-up study. Comprehensive Psychiatry. 2024;132:152478.","DOI":"10.1016\/j.comppsych.2024.152478"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Gunderson JG, Stout RL, McGlashan TH et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Archives of General Psychiatry. 2011;68(8):827\u2013837.","DOI":"10.1001\/archgenpsychiatry.2011.37"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Zanarini MC, Reichman CA, Frankenburg FR, Reich DB, Fitzmaurice G. The course of eating disorders in patients with borderline personality disorder: a 10-year follow-up study. Int J Eat Disord. 2010;43(3):226\u2013232. doi: 10.1002\/eat.20689.","DOI":"10.1002\/eat.20689"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Zanarini MC, H\u00f6rz S, Frankenburg FR, Weingeroff J, Reich DB, Fitzmaurice G. The 10-year course of PTSD in borderline patients and axis II comparison subjects. Acta Psychiatr Scand. 2011;124(5):349\u2013356. doi: 10.1111\/j.1600-0447.2011.01717.x.","DOI":"10.1111\/j.1600-0447.2011.01717.x"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. Time to attainment of recovery from borderline personality disorder and stability of recovery: A 10-year prospective follow-up study. Am J Psychiatry. 2010;167(6):663\u2013667. doi: 10.1176\/appi.ajp.2009.09081130.","DOI":"10.1176\/appi.ajp.2009.09081130"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Yuan S, Tirrell E, Gobin AP, Carpenter LL. Effect of Previous Electroconvulsive Therapy on Subsequent Response to Transcranial Magnetic Stimulation for Major Depressive Disorder. Neuromodulation. 2020;23(3):393\u2013398. doi: 10.1111\/ner.13046.","DOI":"10.1111\/ner.13046"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Cristancho MA, Helmer A, Connolly R, Cristancho P, O\u2019Reardon JP. Transcranial magnetic stimulation maintenance as a substitute for maintenance electroconvulsive therapy: a case series. J Ect. 2013;29(2):106\u2013108.","DOI":"10.1097\/YCT.0b013e31827a70ba"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Noda Y, Daskalakis ZJ, Ramos C, Blumberger DM. Repetitive transcranial magnetic stimulation to maintain treatment response to electroconvulsive therapy in depression: a case series. Frontiers in Psychiatry. 2013;4:73.","DOI":"10.3389\/fpsyt.2013.00073"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Berlim MT, Van den Eynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: A systematic review and meta-analysis of randomized trials. Depression and Anxiety. 2013;30(7):614\u2013623.","DOI":"10.1002\/da.22060"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CH, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019;364","DOI":"10.1136\/bmj.l1079"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Strandberg P, Nordenskj\u00f6ld A, Bod\u00e9n R, Ekman CJ, Lundberg J, Popiolek K. Electroconvulsive Therapy Versus Repetitive Transcranial Magnetic Stimulation in Patients With a Depressive Episode: A Register-Based Study. J Ect. 2024;40(2):88\u201395. doi: 10.1097\/yct.0000000000000971.","DOI":"10.1097\/yct.0000000000000971"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Silva P, Cavieres \u00c1, Humpston C. The phenomenology of auditory verbal hallucinations in schizophrenia and the challenge from pseudohallucinations. Frontiers in Psychiatry. 2022;13:826654.","DOI":"10.3389\/fpsyt.2022.826654"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Toh WL, Thomas N, Rossell SL. Auditory verbal hallucinations in bipolar disorder (BD) and major depressive disorder (MDD): A systematic review. J Affect Disord. 2015;184:18\u201328. doi: 10.1016\/j.jad.2015.05.040.","DOI":"10.1016\/j.jad.2015.05.040"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Clifford G, Dalgleish T, Hitchcock C. Prevalence of auditory pseudohallucinations in adult survivors of physical and sexual trauma with chronic post-traumatic stress disorder (PTSD) Behaviour Research and Therapy. 2018;111:113\u2013118.","DOI":"10.1016\/j.brat.2018.10.015"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Minarikova KB, Prasko J, Holubova M et al. Hallucinations and other psychotic symptoms in patients with borderline personality disorder. Neuropsychiatric Disease and Treatment. 2022;18:787.","DOI":"10.2147\/NDT.S360013"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:37Z","timestamp":1791315217000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/electroconvulsive-therapy-ketamine-and-esketamine-in-a-patient-with-major-depressive-disorder-and-multiple-comorbidities-a-case-report-over-10-year-treatment-from-adolescence-to-adulthood\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4534","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}